Literature DB >> 3366841

Analysis of vinca alkaloids in plasma and urine using high-performance liquid chromatography with electrochemical detection.

D E Vendrig1, J Teeuwsen, J J Holthuis.   

Abstract

The reversed-phase high-performance liquid chromatography with electrochemical detection was used to quantify plasma and urine levels of vinblastine, vincristine, vindesine and a metabolite of vinblastine, desacetylvinblastine. Sample clean-up consisted of solid-phase extraction with a Bond Elut CN column. The extracts were separated on a Hypersil ODS column. The mobile phase consisted of a mixture of methanol and 10 mM phosphate buffer (pH 7.0). The limit of sensitivity using electrochemical detection was 100 pg on-column for all compounds with a signal-to-noise ratio of 3. Quantification of the compounds in human plasma and urine was possible down to 1 ng/ml (ca. 1 pmol). Pharmacokinetic results show that the sensitivity of the method is adequate for drug monitoring in clinical research.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3366841     DOI: 10.1016/s0378-4347(00)81078-6

Source DB:  PubMed          Journal:  J Chromatogr


  5 in total

1.  Population pharmacokinetic model development and exposure-response analysis of vincristine in patients with malignant lymphoma.

Authors:  Toshiaki Igarashi; Shinji Kishi; Naoko Hosono; Takashi Higashi; Takahiro Iwao; Ryoichi Yano; Hitoshi Tsukamoto; Nobuyuki Goto; Takahiro Yamauchi; Takanori Ueda
Journal:  Cancer Chemother Pharmacol       Date:  2021-01-08       Impact factor: 3.333

Review 2.  Preclinical and clinical pharmacology of vinca alkaloids.

Authors:  X J Zhou; R Rahmani
Journal:  Drugs       Date:  1992       Impact factor: 9.546

Review 3.  The current and future place of vinorelbine in cancer therapy.

Authors:  E Cvitkovic; J Izzo
Journal:  Drugs       Date:  1992       Impact factor: 9.546

4.  A phase II study of vinblastine in combination with acrivastine in patients with advanced renal cell carcinoma.

Authors:  J Berlin; A C King; K Tutsch; J W Findlay; P Kohler; M Collier; N J Clendeninn; G Wilding
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

5.  Phase I study of 21 days continuous infusion with vindesine.

Authors:  E G de Vries; E F Smit; D E Vendrig; J J Holthuis; N H Mulder
Journal:  Br J Cancer       Date:  1989-03       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.